Results 191 to 200 of about 181,087 (306)

Harnessing chimeric antigen receptor macrophages against solid tumors. [PDF]

Cancer Commun (Lond)
Wang M, Qin Z, Bian XW, Shi Y.
europepmc   +1 more source

Anti-Chimeric Antigen Receptor Antibody [PDF]

, 2020
openaire   +1 more source

Operationalizing Access for Chimeric Antigen Receptor T cell Therapies: A Cross-functional Perspective. [PDF]

Mayo Clin Proc Innov Qual Outcomes
Singh S, Greulich C, Perez A, Terrell K, Walz-Jensen J, Dalzell MD.   +5 more
europepmc   +1 more source

Patients' and caregivers' perspectives on preparedness for and experience with chimeric antigen receptor T-cell therapy. [PDF]

Oncologist
Barata A, Coffey B, Amonoo HL, Traeger L, Nelson AM, Johnson PC, Dhwale TM, Karpinski K, Jim HSL, El-Jawahri A.   +9 more
europepmc   +1 more source

CXCR3 enhanced murine chimeric antigen receptor T cells in the treatment of solid tumors. [PDF]

Transl Cancer Res
Zhang X, Zhu L, Wang Q, Xu Q, Wang X, Yu F.   +5 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

Immunotherapy of chimeric antigen receptor NK cells: status and its promising future. [PDF]

Front Immunol
Wang F, Huang Z, Feng X, Shi M.
europepmc   +1 more source

Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome

Arthritis &Rheumatology, EarlyView.
Serum cytokine profiling was performed using Luminex (48 cytokines) and ELISA (5 cytokines). Assessment of key cytokines (IFN‐α, IL‐18, IL‐6, CXCL9) delineated five dominant inflammatory patterns: I, IFN‐α–dominant CSS; II, IL‐18–dominant CSS; III, IL‐6–dominant CSS; IV, IFN‐γ–dominant CSS; and V, IL‐6 & IFN‐γ intermediate CSS.
Shuya Kaneko, Maho Hatano, Asami Shimbo, Futaba Miyaoka, Hitoshi Irabu, Yuko Akutsu, Yuko Hayashi, Mao Mizuta, Yasuo Nakagishi, Keiji Akamine, Naomi Iwata, Kenji Furuno, Takayuki Tanaka, Kazuyuki Ueno, Shuhei Fujita, Koji Yokoyama, Toshinori Minato, Kazushi Izawa, Takahiro Yasumi, Tadashi Matsubayashi, Tadashi Hosoya, Hiroki Nishikawa, Junya Fujimura, Ryoko Asano, Yuko Sugita, Kenichi Watanabe, Anna Kobayashi, Takuya Endo, Katsuhide Eguchi, Ryuta Nishikomori, Ryuhei Yasuoka, Takaki Asano, Miyako Kanno, Kazuya Hamada, Yuji Fujita, Daisuke Hayashi, Shojiro Watanabe, Takeshi Shiba, Shinsuke Yasuda, Masaaki Mori, Hirokazu Kanegane, Masatoshi Takagi, Masaki Shimizu   +42 more
wiley   +1 more source

AMPK agonism optimizes the in vivo activation and antileukemic efficacy of chimeric antigen receptor T cells. [PDF]

J Immunother Cancer
Braverman E, Qin M, Ampudia-Mesias E, Schuler HT, Brown H, Murdych L, Titus A, MacLean A, Kanagala B, Wittmann C, Ramgopal A, Kemp F, Mullet SJ, Yang A, Poholek AC, Gelhaus S, Byersdorfer C.   +16 more
europepmc   +1 more source

Sjögren Disease—B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell–Targeted Therapies

Arthritis &Rheumatology, EarlyView.
Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no US Food and Drug Administration (FDA)‐approved disease‐modifying therapies for SjD. In this review, we
Rachael A. Gordon, Sara S. McCoy
wiley   +1 more source